Literature DB >> 17428239

Ultrasound probe positioning to minimize the risk of recto-urethral fistula during cryosurgical ablation of prostate cancer.

J Stephen Jones1.   

Abstract

OBJECTIVE: To evaluate the ability to increase the distance between the rectal mucosa and prostate, and thus decrease the risk of recto-urethral fistula, and to improve the ability to adequately freeze beyond the prostatic capsule during cryosurgical ablation for prostate cancer. PATIENTS AND METHODS: The transrectal ultrasound probe was manipulated to increase the distance from the rectal mucosa to prostate in 28 men scheduled for cryosurgical ablation for localized prostate cancer. Ten patients were treated for local recurrence after previous definitive radiotherapy, and cryosurgery was chosen as the primary treatment for the remainder.
RESULTS: The mean (range) distance from the rectal mucosa to the prostate when the probe was securely applied to the rectal wall was 2.5 (1-7) mm, and could be extended to 9.6 (7-14) mm before the ultrasonogram quality diminished enough to impede accurate placing of the cryoprobe. The mean distance gained as a margin of error was 7.1 (4-12) mm (P < 0.001). In no patient was it felt that visualization during the freezing cycles was impaired. No recto-urethral fistula was identified.
CONCLUSION: The manoeuvres described here allow the surgeon to freeze beyond the prostatic capsule while maintaining a visible distance from rectal wall. The extra distance created by this manoeuvre might reduce the risk of recto-urethral fistula, and potentially improve tumour control in the posterior aspect of the prostate, based on the ability to freeze beyond the capsule to reach lethal temperatures in all prostatic tissue.

Entities:  

Mesh:

Year:  2007        PMID: 17428239     DOI: 10.1111/j.1464-410X.2007.06874.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.

Authors:  Pierre De Marini; Roberto Luigi Cazzato; Julien Garnon; Thibault Tricard; Guillaume Koch; Georgia Tsoumakidou; Nitin Ramamurthy; Hervé Lang; Afshin Gangi
Journal:  Br J Radiol       Date:  2019-04-09       Impact factor: 3.039

2.  Does the type of cryoprobe affect oncological and functional outcomes in men with clinically localized prostate cancer treated with primary whole gland prostate cryoablation?

Authors:  Tarek Taha; Wei Phin Tan; Ahmed Elshafei; Alireza Aminsharifi; Robert Given; Michael L Cher; Thomas J Polascik
Journal:  Curr Urol       Date:  2021-05-04

3.  Primary cryoablation for Gleason 8, 9, or 10 localized prostate cancer: Biochemical and local control outcomes from the Cryo OnLine database registry.

Authors:  J Stephen Jones; John C Rewcastle
Journal:  Indian J Urol       Date:  2008-10

Review 4.  Percutaneous MR-guided prostate cancer cryoablation technical updates and literature review.

Authors:  Pierre de Marini; Roberto Luigi Cazzato; Julien Garnon; Behnam Shaygi; Guillaume Koch; Pierre Auloge; Thibault Tricard; Hervé Lang; Afshin Gangi
Journal:  BJR Open       Date:  2019-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.